Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily known for its key role in the regulation of low-density lipoprotein (LDL) metabolism through hepatic degradation of the LDL receptor (LDLR).1 PCSK9 may however contribute to lipoprotein metabolism in a number of other ways beyond its immediate effects on LDLR activity and LDL-cholesterol (LDL-C) levels.2 Atherogenic dyslipidemia represents an imbalance between excess circulating levels of cholesterol in the form of apolipoprotein (apo) B-containing relative to apo A-I-containing lipoproteins, which primarily involve LDL and high-density lipoprotein (HDL) respectively.

Source: Journal of Clinical Lipidology - July 26, 2023 Category: Lipidology Authors: Maryam Darabi, Marie Lhomme, Maharajah Ponnaiah, Maja Pu čić-Baković, Isabelle Guillas, Eric Frisdal, Randa Bittar, Mikaël Croyal, Lucrèce Matheron-Duriez, Lucie Poupel, Dominique Bonnefont-Rousselot, Corinne Frere, Mathilde Varret, Michel Krempf, Be Tags: Original Research Source Type: research